Skip to main content
Erschienen in: PharmacoEconomics 4/2002

01.04.2002 | Original Research Article

Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma

verfasst von: Alan J. Zillich, Dr Karen Blumenschein, Magnus Johannesson, Patricia Freeman

Erschienen in: PharmacoEconomics | Ausgabe 4/2002

Einloggen, um Zugang zu erhalten

Abstract

Objective: The primary objective was to evaluate the relationship between willingness-to-pay (WTP), quality-of-life (QOL), and disease-severity measures in patients with asthma. The hypothesis studied was that patients with asthma with more severe disease are willing to pay more for a hypothetical cure of asthma than those with less severe disease.
Design setting/Patients and participants: One hundred patients with asthma were recruited from community pharmacies in Kentucky for 30-minute face-to-face interviews.
Interventions: Spirometry assessed objective disease severity in terms of pulmonary function, while a multiple choice question measured subjective disease severity. The Medical Outcomes Study 36-item Short Form (SF-36) health survey and Asthma Technology of Patient Experience (Asthma TyPE) measured quality of life. WTP was obtained via a dichotomous choice contingent valuation question.
Results: In this exploratory evaluation, WTP was significantly related to both objective disease severity (p = 0.02) and subjectively assessed disease severity (p = 0.01). For objective disease severity the mean monthly WTP was $US90 for mild asthma, $US131 for moderate asthma and $US331 for severe asthma and for subjective disease severity the mean monthly WTP was $US48 for mild asthma, $US166 for moderate asthma and $US241 for severe asthma.
Conclusions: The results suggest that the WTP for a cure from asthma is related to both objective and subjective disease severity. These findings contribute to the case for construct validity of the dichotomous choice contingent valuation method in the healthcare sector.
Literatur
1.
Zurück zum Zitat Johannesson M. Theory and methods of economic evaluation of health care. Boston (MA): Kluwer Academic Publishers, 1996 Johannesson M. Theory and methods of economic evaluation of health care. Boston (MA): Kluwer Academic Publishers, 1996
2.
Zurück zum Zitat Mitchell RC, Carson RT. Using surveys to value public goods: the CV method. Baltimore (MD): John Hopkins Press, 1989 Mitchell RC, Carson RT. Using surveys to value public goods: the CV method. Baltimore (MD): John Hopkins Press, 1989
3.
Zurück zum Zitat Reardon G, Pathak DS. Contingent valuation of pharmaceutical and pharmacy services-methodological considerations. J Soc Adm Pharm 1989; 6: 83–90 Reardon G, Pathak DS. Contingent valuation of pharmaceutical and pharmacy services-methodological considerations. J Soc Adm Pharm 1989; 6: 83–90
4.
Zurück zum Zitat Diener A, O’Brien B, Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Econ 1998; 7: 313–26PubMedCrossRef Diener A, O’Brien B, Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Econ 1998; 7: 313–26PubMedCrossRef
5.
Zurück zum Zitat Elixhauser A, Halpern M, Schmier J, et al. Health care CBA and CEA from 1991–1996: an updated bibliography. Med Care 1998; 36: MS1–9PubMedCrossRef Elixhauser A, Halpern M, Schmier J, et al. Health care CBA and CEA from 1991–1996: an updated bibliography. Med Care 1998; 36: MS1–9PubMedCrossRef
6.
Zurück zum Zitat O’Brien B, Goeree R, Gafni A, et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care 1998; 36: 370–84PubMedCrossRef O’Brien B, Goeree R, Gafni A, et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care 1998; 36: 370–84PubMedCrossRef
7.
Zurück zum Zitat O’Brien B, Viramontes JL. WTP: a valid and reliable measure of health state preference. Med Decis Making 1994; 14: 289–97PubMedCrossRef O’Brien B, Viramontes JL. WTP: a valid and reliable measure of health state preference. Med Decis Making 1994; 14: 289–97PubMedCrossRef
8.
Zurück zum Zitat Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 1998; 80: 189–94PubMedCrossRef Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 1998; 80: 189–94PubMedCrossRef
9.
Zurück zum Zitat Stavem K. Willingness to pay: a feasible method for assessing treatment benefits in epilepsy? Seizure 1999; 8 (1): 14–9PubMedCrossRef Stavem K. Willingness to pay: a feasible method for assessing treatment benefits in epilepsy? Seizure 1999; 8 (1): 14–9PubMedCrossRef
10.
Zurück zum Zitat Zethraeus N, Johannesson M, Henriksson P, et al. The impact of hormone replacement therapy on the quality of life and willingness to pay. Br J Obstet Gynaecol 1997; 104 (10): 1191–5PubMedCrossRef Zethraeus N, Johannesson M, Henriksson P, et al. The impact of hormone replacement therapy on the quality of life and willingness to pay. Br J Obstet Gynaecol 1997; 104 (10): 1191–5PubMedCrossRef
11.
Zurück zum Zitat Narbro K, Sjostrom L. Willingness to pay for obesity treatment. Int J Technol Assess Health Care 2000; 16 (1): 50–9PubMedCrossRef Narbro K, Sjostrom L. Willingness to pay for obesity treatment. Int J Technol Assess Health Care 2000; 16 (1): 50–9PubMedCrossRef
12.
Zurück zum Zitat Kartman B, Andersson F, Johanneson M. Willingness to pay for reductions in angina pectoris attacks. Med Decis Making 1996; 16 (3): 248–53PubMedCrossRef Kartman B, Andersson F, Johanneson M. Willingness to pay for reductions in angina pectoris attacks. Med Decis Making 1996; 16 (3): 248–53PubMedCrossRef
13.
Zurück zum Zitat Chestnut LG, Keller LR, Lambert WE, et al. Measuring heart patients’ willingness to pay for changes in angina symptoms. Med Decis Making 1996; 16 (1): 65–77PubMedCrossRef Chestnut LG, Keller LR, Lambert WE, et al. Measuring heart patients’ willingness to pay for changes in angina symptoms. Med Decis Making 1996; 16 (1): 65–77PubMedCrossRef
14.
Zurück zum Zitat Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141 (6): 1067–75PubMedCrossRef Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141 (6): 1067–75PubMedCrossRef
15.
Zurück zum Zitat National Oceanic and Atmospheric Administration. Report of the NOAA panel on contingent valuation. Fed Regist 1993; 58: 4602–14 National Oceanic and Atmospheric Administration. Report of the NOAA panel on contingent valuation. Fed Regist 1993; 58: 4602–14
16.
Zurück zum Zitat Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988; 26: 724–35PubMedCrossRef Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988; 26: 724–35PubMedCrossRef
17.
Zurück zum Zitat Bousquet J, Knani J, Dhivert H, et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 1994; 14 (2 Pt 1): 371–5 Bousquet J, Knani J, Dhivert H, et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 1994; 14 (2 Pt 1): 371–5
18.
Zurück zum Zitat Asthma TyPE, Health Outcomes Institute, 1994 Asthma TyPE, Health Outcomes Institute, 1994
20.
Zurück zum Zitat Cameron TM. A new paradigm for valuing non-market goods using referendum data: maximum likelihood estimation by censored logistic regression. J Environ Econ Manage 1988; 15: 355–79CrossRef Cameron TM. A new paradigm for valuing non-market goods using referendum data: maximum likelihood estimation by censored logistic regression. J Environ Econ Manage 1988; 15: 355–79CrossRef
21.
Zurück zum Zitat Greene WH. Econometric analysis. 2nd ed. New York (NY): Macmillan, 1993 Greene WH. Econometric analysis. 2nd ed. New York (NY): Macmillan, 1993
22.
Zurück zum Zitat Newbold P. Statistics for business and economics. 3rd ed. Englewoods Cliffs (NJ): Prentice-Hall, 1991 Newbold P. Statistics for business and economics. 3rd ed. Englewoods Cliffs (NJ): Prentice-Hall, 1991
23.
Zurück zum Zitat Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147: 832–8PubMed Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147: 832–8PubMed
24.
Zurück zum Zitat Apter AJ, Reisine ST, Affleck G, et al. The influence of demographic and socioeconomic factors on health-related quality of life in asthma. J Allergy Clin Immunol 1999; 103: 72–8PubMedCrossRef Apter AJ, Reisine ST, Affleck G, et al. The influence of demographic and socioeconomic factors on health-related quality of life in asthma. J Allergy Clin Immunol 1999; 103: 72–8PubMedCrossRef
25.
Zurück zum Zitat Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of the impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76–83PubMedCrossRef Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of the impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76–83PubMedCrossRef
Metadaten
Titel
Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma
verfasst von
Alan J. Zillich
Dr Karen Blumenschein
Magnus Johannesson
Patricia Freeman
Publikationsdatum
01.04.2002
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 4/2002
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200220040-00004

Weitere Artikel der Ausgabe 4/2002

PharmacoEconomics 4/2002 Zur Ausgabe

Review Article

Enoxaparin